🇺🇸 FDA
Pipeline program

Namodenoson 25mg

CF102-222PC

Phase 2 small_molecule active

Quick answer

Namodenoson 25mg for Pancreatic Adenocarcinoma is a Phase 2 program (small_molecule) at Can-Fite BioPharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Can-Fite BioPharma
Indication
Pancreatic Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials